Gideon M. Blumenthal

16.2k citations

119 papers · 7.5k indexed · 6 hit papers · h-index 47

Oncology top 0.5%
Pulmonary and Respiratory Medicine top 0.5%
Molecular Biology top 5%
Cancer Research top 1%
Immunology top 2%

Co-authors: Richard Pazdur Phillip A. Dennis Patricia Keegan M. Christine Hollander Kun He Dickran Kazandjian Jaclyn LoPiccolo Wendy B. Bernstein
Topics: Lung Cancer Treatments and Mutations (44 papers)Cancer Immunotherapy and Biomarkers (31 papers)Cancer Genomics and Diagnostics (26 papers)
Cited by: Oncology Cancer Research Pulmonary and Respiratory Medicine
Journals: Journal of Clinical Oncology Nature reviews. Cancer Blood
Partner nations: United States Thailand Switzerland

In The Last Decade

Gideon M. Blumenthal

117 papers receiving 7.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations

2008 656 citations Gideon M. Blumenthal et al. profile →
PTEN loss in the continuum of common cancers, rare syndromes and mouse models

2011 631 citations Gideon M. Blumenthal et al. profile →
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

2016 337 citations Dickran Kazandjian, Gideon M. Blumenthal et al. The Oncologist profile →
FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1

2016 285 citations Gideon M. Blumenthal, Xiaoping Jiang et al. The Oncologist profile →
FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia

2018 252 citations Aviva C. Krauss, Xin Gao et al. Clinical Cancer Research profile →
PTEN hamartoma tumor syndromes

2008 205 citations Gideon M. Blumenthal et al. profile →

Peers

Countries citing papers authored by Gideon M. Blumenthal

Since Specialization

Citations

This map shows the geographic impact of Gideon M. Blumenthal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gideon M. Blumenthal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gideon M. Blumenthal more than expected).

Fields of papers citing papers by Gideon M. Blumenthal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gideon M. Blumenthal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gideon M. Blumenthal. The network helps show where Gideon M. Blumenthal may publish in the future.

Co-authorship network of co-authors of Gideon M. Blumenthal

This figure shows the co-authorship network connecting the top 25 collaborators of Gideon M. Blumenthal. A scholar is included among the top collaborators of Gideon M. Blumenthal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gideon M. Blumenthal. Gideon M. Blumenthal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of sacituzumab tirumotecan monotherapy in patients with advanced urothelial carcinoma who progressed on or after prior anti-cancer therapies: Report from the phase 1/2 MK-2870-001 study. 2025 ·Journal of Clinical Oncology ·Dingwei Ye,Shusuan Jiang,Yuan Fang,Fangjian Zhou,Kui Jiang,Xiaoping Zhang,(unknown),Lasika Seneviratne,Guohua Yu,Mingjun Zhang,Shuang Zhang,Mei Chen,Gideon M. Blumenthal,(unknown),Yaling Li,Dian Jing,(unknown),Yanxia Shi	5
2	Optimizing public-private partnerships to support clinical cancer research 2024 ·JNCI Journal of the National Cancer Institute ·Roy S. Herbst,Gideon M. Blumenthal,Samir N. Khleif,Scott M. Lippman,Neal J. Meropol,(unknown),Lawrence N. Shulman,(unknown),Meina Wang,Robert A. Winn,Richard L. Schilsky	1
3	Approvals in 2019: international review and a new agnostic molecular entity 2020 ·Nature Reviews Clinical Oncology ·Harpreet Singh,Gideon M. Blumenthal,Richard Pazdur	7
4	Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group 2020 ·Clinical Lung Cancer ·Patrick M. Forde,P. Bonomi,Alice T. Shaw,Gideon M. Blumenthal,Andrea Ferris,(unknown),Allen S. Melemed,Upal Roy,Anuradha Ramamoorthy,Qi Liu,Timothy F. Burns,Justin F. Gainor,Christine M. Lovly,Zofia Piotrowska,Jonathan M. Lehman,Wendy Selig	10
5	FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome 2019 ·Clinical Cancer Research ·Yvette L. Kasamon,Haiyan Chen,R. Angelo de Claro,Lei Nie,Jingjing Ye,Gideon M. Blumenthal,Ann T. Farrell,Richard Pazdur	51
6	FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease 2019 ·The Oncologist ·Donna Przepiorka,Lola Luo,Sriram Subramaniam,Junshan Qiu,Ramadevi Gudi,Lea Cunningham,Lei Nie,Rupert W. Leong,Lian Ma,Christopher M. Sheth,Albert Deisseroth,Kirsten B. Goldberg,Gideon M. Blumenthal,Richard Pazdur	91
7	FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm 2019 ·Clinical Cancer Research ·Emily Y. Jen,Xin Gao,Liang Li,Luning Zhuang,Natalie E. Simpson,Baikuntha Aryal,Rong Wang,Donna Przepiorka,Yuan Li Shen,Rupert W. Leong,(unknown),Christopher M. Sheth,(unknown),Kirsten B. Goldberg,Ann T. Farrell,Gideon M. Blumenthal,Richard Pazdur	65
8	Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer 2019 ·PLoS ONE ·Tristan M. Sissung,Arun Rajan,Gideon M. Blumenthal,David J. Liewehr,Seth M. Steinberg,(unknown),Giuseppe Giaccone,William D. Figg	7
9	CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis 2019 ·The Lancet Oncology ·Jennifer Gao,Joyce Cheng,Erik Bloomquist,(unknown),Suparna Wedam,Harpreet Singh,Laleh Amiri‐Kordestani,Amna Ibrahim,Rajeshwari Sridhara,Kirsten B. Goldberg,Marc R. Theoret,Paul G. Kluetz,Gideon M. Blumenthal,Richard Pazdur,Julia A. Beaver,Tatiana M. Prowell	194
10	FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemiabreakdown → 2018 ·Clinical Cancer Research ·Aviva C. Krauss,Xin Gao,Liang Li,Michael L. Manning,Paresma Patel,Wentao Fu,Kumar G. Janoria,Gerlie Gieser,David A. Bateman,Donna Przepiorka,Yuan Li Shen,Stacy S. Shord,Christopher M. Sheth,Anamitro Banerjee,Jiang Liu,Kirsten B. Goldberg,Ann T. Farrell,Gideon M. Blumenthal,Richard Pazdur	252
11	FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations 2018 ·The Oncologist ·Lauretta Odogwu,Luckson Mathieu,Gideon M. Blumenthal,Erin Larkins,Kirsten B. Goldberg,(unknown),Karen E. Bijwaard,Eunice Lee,Reena Philip,Xiaoping Jiang,Lisa Rodríguez,Amy E. McKee,Patricia Keegan,Richard Pazdur	166
12	Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis 2018 ·The Lancet Oncology ·Julia A. Beaver,Maitreyee Hazarika,Flora Mulkey,Sirisha L. Mushti,Huanyu Chen,Kun He,Rajeshwari Sridhara,Kirsten B. Goldberg,Meredith K. Chuk,(unknown),Jennie Chang,Amy Barone,Sanjeeve Balasubramaniam,Gideon M. Blumenthal,Patricia Keegan,Richard Pazdur,Marc R. Theoret	112
13	Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria 2018 ·Journal of Thoracic Oncology ·Philip Bonomi,Gideon M. Blumenthal,Andrea Stern Ferris,David J. Stewart,Wendy Selig,Lee M. Krug,Jeff Allen,Gwynn Ison,Corey J. Langer,Allen S. Melemed,Lauretta Odogwu,Upal Roy,Alan Sandler	10
14	FDA analyses of survival in older adults with metastatic non–small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies 2018 ·Seminars in Oncology ·Shanthi Marur,Harpreet Singh,Pallavi S. Mishra‐Kalyani,Erin Larkins,Patricia Keegan,Rajeshwari Sridhara,Gideon M. Blumenthal,Richard Pazdur	66
15	FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation 2017 ·The Oncologist ·Lauretta Odogwu,Luckson Mathieu,Kirsten B. Goldberg,Gideon M. Blumenthal,Erin Larkins,Mallorie H. Fiero,Lisa Rodríguez,Karen E. Bijwaard,Eunice Y. Lee,Reena Philip,(unknown),Martha Donoghue,Patricia Keegan,Amy S. McKee,Richard Pazdur	49
16	Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy 2017 ·Annals of Oncology ·Caroline E. McCoach,Gideon M. Blumenthal,(unknown),Adrian Myers,Shenghui Tang,R. Sridhara,Patricia Keegan,Richard Pazdur,Robert C. Doebele,Dickran Kazandjian	63
17	Approvals in 2016: the march of the checkpoint inhibitors 2017 ·Nature Reviews Clinical Oncology ·Gideon M. Blumenthal,Richard Pazdur	13
18	An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies 2016 ·Clinical Cancer Research ·Julia A. Beaver,Abraham Tzou,Gideon M. Blumenthal,Amy E. McKee,Geoffrey Kim,Richard Pazdur,Reena Philip	26
19	Clinician Perspectives on Current Issues in Lung Cancer Drug Development 2016 ·Journal of Thoracic Oncology ·Saiama N. Waqar,Philip Bonomi,Ramaswamy Govindan,Fred R. Hirsch,Gregory J. Riely,Vassiliki A. Papadimitrakopoulou,Dickran Kazandjian,Sean Khozin,Erin Larkins,(unknown),Shakun Malik,Leora Horn,Andrea Ferris,Alice T. Shaw,Pasi A. Jänne,Tony Mok,Roy S. Herbst,Patricia Keegan,Richard Pazdur,Gideon M. Blumenthal	8
20	Assessment of benefits and risks in development of targeted therapies for cancer — The view of regulatory authorities 2014 ·Molecular Oncology ·Francesco Pignatti,Bertil Jönsson,Gideon M. Blumenthal,Robert Justice	17

About Gideon M. Blumenthal

Gideon M. Blumenthal is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 119 papers that have together received 7.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (44 papers), Cancer Immunotherapy and Biomarkers (31 papers) and Cancer Genomics and Diagnostics (26 papers). The work is most often cited by research in Oncology (4.0k citations), Cancer Research (1.3k citations) and Pulmonary and Respiratory Medicine (2.6k citations). Gideon M. Blumenthal has collaborated with scholars based in United States, Thailand and Switzerland. Frequent co-authors include Richard Pazdur, Phillip A. Dennis, Patricia Keegan, M. Christine Hollander, Kun He, Dickran Kazandjian, Jaclyn LoPiccolo, Wendy B. Bernstein, Kirsten B. Goldberg and Sean Khozin. Their work appears in journals such as Journal of Clinical Oncology, Nature reviews. Cancer and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact